Louisiana Plaintiffs Allege GSK Hid Risk of Birth Defects Posed by Off-Label Use of Zofran

ALEXANDRIA, La. — Two women have sued GlaxoSmithKline in Louisiana federal court, accusing it of promoting its anti-nausea drug Zofran as an off-label morning sickness remedy while concealing the risk that ingestion of the drug by pregnant women can cause serious birth defects.

In a June 8 complaint filed in the U.S. District Court for the Western District of Louisiana, plaintiffs Stacy Coughlin and Ashley Swann allege that their ingestion of Zofran while pregnant caused their daughters to be born with serious and dangerous respiratory and heart defects.

These defects include perimembranous ventricular septal defect, atrial septal defect, intermittent …